- Conditions
- Type 1 Diabetes, Dawn Phenomenon
- Interventions
- Lantus (glargine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Interventions
- G-Pen, Lilly Glucagon
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more
- Conditions
- Hypoglycemia
- Interventions
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 1 Diabetes Mellitus With Hypoglycemia
- Interventions
- Glucagon, Insulin
- Drug
- Lead sponsor
- Abvance Therapeutics
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
- Drug · Device
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes
- Interventions
- Xeris glucagon, Lilly glucagon
- Drug
- Lead sponsor
- Steven J. Russell, MD, PhD
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more